Platinum partner: CSL Behring
CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent haemolytic disease of the newborn.
www.cslbehring.co.uk
Platinum partner: Shire
At Shire, we believe there’s a better outlook for the people we help. We’re dedicated to serving patients with rare diseases and highly specialised conditions. We have expertise in difficult to treat core therapeutic areas such as Immunology and Hereditary Angioedema (HAE). Our therapeutic expertise and entrepreneurial, patient-driven culture mean that we can accelerate innovation and make a meaningful difference to the lives of our patients and their families.
At UKPIN on the 7-8th December you will be able to learn more about Shire’s Immunology products which include treatments for Primary Immunodeficiency (PID) and Secondary Immunodeficiency (SID) as well as HAE. Come and learn more about how Shire is committed to providing a comprehensive range of immunoglobulin and HAE therapies on booth numbers 5 and 3.
www.shirepharmaceuticals.co.uk
Exhibitors:
BD Biosciences
BD Biosciences deliver innovative tools to clinicians in diagnostics, disease management, research and drug discovery. Our reagents and flow cytometry systems help scientists understand the intricacies of human immune function, with our focus on advancing cellular analysis with fluorescence-activated cell analysers and sorters, monoclonal antibodies, as well as reagent systems for clinical diagnostics. Our aim is to provide reliable, accurate and repeatable results – test to test, instrument to instrument and site to site. Instrument installations, bespoke antibody formulations, and expert applications support allow us to deliver holistic solutions to meet diverse needs in the clinical, industrial and research laboratory.
Binding Site
The specialist proteins on which we focus include: Freelite® – the proven, trusted polyclonal serum free light chain assays recommended by numerous UK and International guidelines for diagnosis, prognosis and monitoring of B cell dyscrasias; Hevylite® – accurate, quantitative measurement of intact immunoglobulins for improved monitoring of Multiple Myeloma; Immunoglobulin subclasses and other serum proteins. All assays can be run on Binding Site’s Optilite® and SPAPLUS® protein systems designed to allow lean throughput with minimum turnaround time.
Binding Site is committed to improving patient lives worldwide through education, collaboration and innovation.
Product Listing
Analysers Haematology
Antisera Immunoassay hardware
Clinical chemistry Immunology Diagnostic kits/reagents
Biotest (UK) Ltd
Biotest is a global company that supplies plasma protein products and biotherapeutic drugs. Our products are primarily used in the therapeutic areas of clinical immunology, haematology and intensive care medicine for patients with serious and often chronic diseases.
Within our areas of specialisation, we start from pre-clinical and clinical development to manufacturing and global marketing. Research, development and production are carried out at our main headquarters in Dreieich, Germany. Biotest products are marketed in over 80 countries globally via our own sales organisations (subsidiaries) in Europe and Brazil, and our global distribution partners.
Biotest (UK) Ltd. based in Longbridge, Birmingham has operated in the UK for more than 40 years. This dedicated UK team is focused on providing therapeutic solutions for our customers, be they patients or healthcare providers. Our presence in the UK is underpinned by our current portfolio, our significant investment in a exciting R&D pipeline and expansion to our manufacturing capability.
www.biotest.com
CSL Behring
CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent haemolytic disease of the newborn.
Grifols UK
Grifols, a global healthcare company, has worked to improve the health and well being of people around the world for more than 75 years. We are committed to producing essential plasma medicines for patients and to providing hospitals, pharmacies and healthcare professionals with the tools, information and services they need to deliver expert medical care.
HAE UK
HAE UK is a support and advocacy group for people and families affected by Hereditary Angioedema or Acquired C1-INH deficiency. We are a registered charity (No/ 1152591) and have a small management team, dedicated Trustees, medical advisors, youth ambassador and some very good volunteers. We aim to help people to live more fulfilling and active lives by managing their condition appropriately. Our motto is ‘living for today…..planning for tomorrow’.
LFB Biopharmaceuticals
Established in the UK in 2015, LFB Biopharmaceuticals is the British subsidiary of the LFB Group, which was founded in France 20 years ago with the aim of developing increasing safety for plasma-derived pharmaceuticals. Today the LFB Group includes companies with expertise in plasma fractionation, cell culture and recombinant technologies. We develop, manufacture and market medicinal products for the treatment of serious, and often rare, diseases in several major therapeutic fields, including Haemostasis, Immunology and Intensive Care.
Octapharma
Octapharma, headquartered in Lachen, Switzerland, is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation since 1983. Its core business is the development and production of human proteins from human plasma and human cell-lines. Octapharma employs approximately 6,000 people worldwide to support the treatment of patients in over 100 countries with products across the following therapeutic areas: Haematology (coagulation disorders), Immunotherapy (immune disorders), Ciritical Care. Octapharma owns five state-of-the-art production facilities in Austria, France, Germany, Sweden and Mexico. For more information visit www.octapharma.co.uk
Pharming Group
Pharming Group is a specialist pharmaceutical company based in the Netherlands.
We use transgenic technology to develop pioneering treatments for rare diseases and unmet medical needs.
Our flagship product, Ruconest® was first approved in 2014 improving the lives of Hereditary Angioedema sufferers around the world.
It is the only recombinant human C1 esterase inhibitor approved for the treatment of HAE attacks, and its unique manufacturing process mitigates the risk of human blood-borne viruses.
We value loyalty, consistency, reliability and are committed to providing continuous supply of high-quality products worldwide, supporting healthcare professionals, always meeting the every-day needs of our patients.
Primary Immunodeficiency UK (PID UK)
PID UK helps individuals and families affected by a primary immunodeficiency by giving practical advice on all aspects of living with a PID, providing condition and topic specific educational material and acting as a patient advocate, ensuring that the PID community’s health needs are understood and addressed by those involved in policy and delivery of healthcare. PID UK is the UK national member of the International Patient Organisation for Primary Immunodeficiencies (IPOPI).
Contact details:
Number: +44 (0)800 987 8986
Email: [email protected]
QPIDS – Royal College of Physicians (RCP) Accreditation Unit
The RCP offers a range of accreditation services, with the aim of improving the quality, safety and outcomes of healthcare, the patient experience and service delivery.
Quality in Primary Immunodeficiency Services (QPIDS) is the accreditation scheme for immunology services in the UK. Services undergo a programme of self-assessment and quality improvement before undergoing a rigorous assessment against the QPIDS standards. Services which are shown to meet the standards are granted accreditation.
Shire
At Shire, we believe there’s a better outlook for the people we help. We’re dedicated to serving patients with rare diseases and highly specialised conditions. We have expertise in difficult to treat core therapeutic areas such as Immunology and Hereditary Angioedema (HAE). Our therapeutic expertise and entrepreneurial, patient-driven culture mean that we can accelerate innovation and make a meaningful difference to the lives of our patients and their families.
At UKPIN on the 7-8th December you will be able to learn more about Shire’s Immunology products which include treatments for Primary Immunodeficiency (PID) and Secondary Immunodeficiency (SID) as well as HAE. Come and learn more about how Shire is committed to providing a comprehensive range of immunoglobulin and HAE the
UKPIPS is a registered charity
and a company limited by guarantee in England, Scotland and Wales.
Its key tasks are to:
- Lessen cases of
irreparable organ damage, caused by diagnostic delay, through advancing
education within the medical community about Primary Antibody Deficiencies
(PADs) and other Primary Immune Deficiencies (PIDs).
- Provide a volunteer
medical panel comprising immunology experts.
- Support those caring for
PAD/PID patients in the community, whether medical or nursing
professionals or informal carers.
- Encourage research into
PAD/PID.
- Provide appropriate and
accurate information for patients with PAD and PID, their carers, partners
and family.
- Promote the social and
medical welfare of those living with PAD / PID.